Clinical Trials Browser

Phase 3 × masitinib × Plasma cell × Clear all

NCT01470131 2018-12-19

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Phase 3 Terminated

Multiple Myeloma, Recurrence